New drug combo targets Hard-to-Treat cancers

NCT ID NCT06571422

Ongoing Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrinkage. The trial is open to adults aged 18-75 with measurable tumors and good organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WJ47156
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase I trial with a small number of participants, so it is primarily testing safety. The drug may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMORS

Contacts and locations

Show contact details

Locations

ICON

Brisbane, Queensland, 4066, Australia
One Clinical

Nedlands, Western Australia, 6009, Australia
SOCRU

Adelaide, South Australia, 5042, Australia
St Vincent's Hospital Sydney

Sydney, New South Wales, 2010, Australia
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.